Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe

• Published in: Clinical pharmacology and therapeutics Vol. 74; no. 2; p. 150
• Main Authors: Majumdar, Anup K, McCrea, Jacqueline B, Panebianco, Deborah L, Hesney, Michael, Dru, James, Constanzer, Marvin, Goldberg, Michael R, Murphy, Gail, Gottesdiener, Keith M, Lines, Christopher R, Petty, Kevin J, Blum, Robert A
• Format: Journal Article
• Language: English
• Published: United States 01.08.2003
• Subjects: Adult; Anti-Anxiety Agents - pharmacokinetics; Antiemetics - pharmacology; Aprepitant; Area Under Curve; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Half-Life; Humans; Male; Midazolam - pharmacokinetics; Morpholines - pharmacology; Neurokinin-1 Receptor Antagonists

Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist. Because aprepitant may be used with a variety of chemotherapeutic agents...